Prior authorization means your plan will pay, but only after your doctor confirms you meet its criteria — typically a documented type 2 diabetes diagnosis, and sometimes that you've tried metformin or another first-line drug first (step therapy). Once approved, Ozempic sits on Tier 3, a mid-to-higher cost tier, so you'll usually have a meaningful copay or coinsurance until you reach your plan's catastrophic threshold.
Ozempic is FDA-approved for diabetes, not weight loss. If it's prescribed off-label purely for weight management, Medicare's statutory weight-loss exclusion applies and the plan won't cover it for that purpose. The weight-loss-branded version of the same molecule, Wegovy, runs into the same wall — it's on only about 1% of plans. See the Wegovy breakdown →
Because coverage is so widespread, most denials are about the prior-authorization paperwork, not the drug itself — a missing diabetes diagnosis code, or step-therapy history that wasn't documented. Making sure your prescriber submits those details up front is usually the difference between an approval and an appeal.
See how Ozempic — or any drug — lands across all Medicare Part D plans: coverage, tier, and prior authorization.
Look up a drug — freePlans use prior authorization to confirm the drug is being used for an approved indication (type 2 diabetes) and, on some plans, that you've tried a first-line option first. Your prescriber submits the request; once approved it's covered on Tier 3.
No. Ozempic is approved for diabetes, and Medicare can't cover any drug used for weight loss by law. For weight management the conversation is about other options — and even Wegovy (the same molecule, branded for weight loss) is excluded.
Generally yes for type 2 diabetes — Mounjaro (tirzepatide) is covered on the large majority of Part D plans, similar to Ozempic. Its weight-loss twin Zepbound is not.
It depends on your plan's Tier 3 cost-share and where you are in the year. Use the lookup to see your plan's tier, then check that tier's copay in your plan documents.